Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from Managed Healthcare Executive® referenced an article published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The article, “Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients With Moderate to Severe AA,” highlighted results from a poster presented at the 2024 American Academy of Dermatology Annual Meeting, which found that the Janus kinase inhibitor deuruxolitinib resulted in hair regrowth in patients with moderate to severe alopecia areata, with efficacy and tolerability.
An article from Pharmacy Times® referenced a resource published by AJMC’s sister site, The Center for Biosimilars®. The page, “The Center for Biosimilars: Biosimilars Approvals,” lists all 49 approved biosimilars in the US, including the name of each drug and the conditions it treats.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Cutting-Edge Eye Care Technologies Highlighted at SECO 2025
February 28th 2025Artificial intelligence, surgical innovations, and wearable technology are transforming eye care, enhancing patient outcomes and clinical efficiency, as discussed during the keynote presentation at the Southeastern Congress of Optometry (SECO) 2025.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Understanding SMA Subtypes and the Impact of Treatment Advances
February 28th 2025The classification of spinal muscular atrophy (SMA) subtypes, the influence of SMN2 gene copies on disease severity, treatment effects on disease progression, age-related differences, long-term management strategies, and adequate muscle function monitoring are all important aspects of SMA care.
Read More